BioLineRx (NASDAQ:BLRX) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate Motixafortide in stem cell mobilization (SCM) for autologous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results